Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type I Gaucher Disease: results of a 48-month longitudinal cohort study

Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type I Gaucher Disease: results of a 48-month longitudinal cohort study. Amer Society Human Genetics. 2006.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.